0001209191-22-005434.txt : 20220128
0001209191-22-005434.hdr.sgml : 20220128
20220128164740
ACCESSION NUMBER: 0001209191-22-005434
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220126
FILED AS OF DATE: 20220128
DATE AS OF CHANGE: 20220128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thomson Mary Christina
CENTRAL INDEX KEY: 0001295674
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 22569594
MAIL ADDRESS:
STREET 1: C/O AVIGEN, INC.
STREET 2: 1301 HARBOR BAY PKWY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
BUSINESS PHONE: (605) 376-8679
MAIL ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-26
0
0001290149
Sierra Oncology, Inc.
SRRA
0001295674
Thomson Mary Christina
C/O SIERRA ONCOLOGY, INC.
1820 GATEWAY DRIVE, SUITE 110
SAN MATEO
CA
94404
0
1
0
0
General Counsel & Secretary
Common Stock
2022-01-26
4
M
0
2000
13.04
A
2000
D
Common Stock
2022-01-26
4
S
0
2000
29.00
D
0
D
Stock Option (Right to Buy)
13.04
2022-01-26
4
M
0
2000
0.00
A
2030-07-28
Common Stock
2000
0
D
Stock Option (Right to Buy)
12.15
2022-01-28
4
A
0
12250
0.00
A
2022-01-28
2030-08-12
Common Stock
12250
12250
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 21, 2022. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
On July 28, 2021, the option vested as to 25% of the total shares granted on July 28, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on July 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares.
/s/ Mary Christina Thomson
2022-01-28